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PART I  
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INTRODUCTION 
Retinopathy of Prematurity (ROP) is a disease affecting the retina of premature 
infants.
1
 
It is one of the leading causes of preventable childhood blindness in India. In our 
country, ROP incidence is between 38 – 51.9 % in low birth weight babies. With 
improved neonatal care and better survival rate of preterm infants, ROP incidence in our 
country is on the increasing trend.
2-4
 
The fundamental pathological process underlying ROP stems from incompletely 
vascularised peripheral retina at birth in preterm babies.
5
 
After birth, ROP evolves slowly over 4-5 weeks and this gives us a small window 
of opportunity for predicting the development of severe ROP and timely interventions to 
improve visual outcome thereby avoiding irreversible blindness.
5
 
ROP incidence increases with decreasing Gestational Age (GA) and Birth Weight 
(BW), however not in all preterm babies. So, there might be other fetal and or maternal 
risk factors influencing the ROP development. These factors may protect or increase the 
probability of development of ROP.
6,7
 
According to revised ET-ROP study, approximately 8% screened babies require 
treatment based on current ROP screening guidelines.
8 
In more than 90% of babies ROP 
is either regressing or never developing.   
2 
 
Although current ablation treatment reduces the incidence of blindness in babies 
with severe stages of ROP, these babies still have poor visual outcome and there exists 
significant impact of the disease on development of eye and vision. 
Recent studies showed that one of the strongest predictors of “severe ROP” is 
“poor postnatal weight gain” in early postnatal period.9,10 However current screening 
protocols does not include this risk factor as a predictor for the development of ROP. 
Identifying a modifiable postnatal risk factor like poor postnatal weight gain by 
simple serial postnatal weight measurements helps in identification of premature babies 
at risk for developing severe ROP more specifically, thereby avoiding unnecessary 
stressful examination to babies not at risk, and also predicting the disease earlier before it 
is diagnosed by regular ocular examination that helps in early intervention and prevention 
of severe vision loss and unfavourable outcome. 
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HISTORY 
Terry was the first to report it in 1942 in American journal of Ophthalmology.
11
 
Dr.Harry Messenger coined the term Retrolental fibroplasia, by which ROP would be 
known for 40 more years. He related it to persistent hyaloid artery and tunica vasculosa 
lentis and embryonic connective tissue growth behind the lens.
12
 
Owens and Owens first reported the case series of infants with Retrolental 
fibroplasia and reported that pathogenesis was not related to congenital abnormalities of 
hyaloid system and it developed postnatally.
13
  
In 1950s, relationship between ROP and supplemental oxygen was discovered. 
Multicentre randomized clinical trial, National Cooperative Study proved the correlation 
to oxygen supplementation which led to reduction of O2 supplementation in neonatal care 
unit that led to reduced ROP incidence. But, this led to increased mortality and morbidity 
of premature infants.
14,15
 
In 1970s, neonatal care unit started using arterial blood gas analysis that enabled 
pediatricians to titrate oxygen concentration of incubator to meet individual oxygen needs 
and led to decreased incidence of ROP.
16
 Morbidity decreased due to rigid oxygen 
curtailment and optimized oxygen concentration.  
 In 1980 ROP began to rise due to more survival rate of preterm babies with 
advancement in neonatal care. 
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INCIDENCE AND PREVALENCE 
 In India, ROP incidence is between 38 – 51.9 % in low birth weight babies. In our 
country, annual live births is around 26 million, of which approximately 8.7% are with 
BW of <2000 grams. This shows that almost 2 million newborns are at risk for ROP.
17 
“Vision 2020 programme” of World Health Organization's has found ROP as one 
of the significant cause of blindness in middle and high income countries.  
Incidence of ROP in gestational age of 24-27 weeks is 89 %. As the gestational 
age increase, ROP incidence decreases.  
ROP incidence in BW of <750gms is 90%. As the BW increases, ROP incidence 
decreases. ROP can be seen in 80 to 90 % of low birth weight babies exposed to oxygen 
therapy. 
This table shows ROP incidence and severity in premature babies with birth weight 
≤1,251 g18–21 
STUDIES No.of babies Any ROP 
(%) 
Prethreshold 
ROP (%) 
Threshold 
ROP (%) 
CRYO-ROP STUDY 4,099 66 18 6 
LIGHT-ROP STUDY 361 70 14 5 
ET-ROP STUDY 6,998 68   
 
5 
 
This table shows the severe ROP incidence among premature babies in CRYO-ROP 
study and ET-ROP study
18-21 
STUDIES Patients Prethreshold 
ROP  (%) 
Plus (%) Zone I ROP 
(%) 
CRYO-ROP STUDY 2,699 27 17 2 
ETROP-ROP STUDY 2,320 37 24 9 
 
 Blind school survey reported that in African countries, severe visual impairment 
due to ROP was zero percent and in Cuba it was 38.6%. Due to poor neonatal services 
the low birth weight babies do not survive to develop ROP in African countries. 
Present ROP epidemic is of concern mostly with developing countries. The reason 
for this is premature babies surviving with more intensive neonatal care units; neonatal 
services have not reached the adequate level of care where the infants are unmonitored 
supplement of oxygen. 
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NORMAL RETINAL VASCULOGENESIS 
The vascular supply of retina consists of:   
1. Choroid vessels that underlie the retina.  
2. Retinal vessels that serve the inner retina.  
Brain and retinal development of the fetus are intimately connected. 
Vision begins – around 28 weeks of GA and  
Visual responses measureable – around 32 weeks of GA.  
Normal retinal vascular development starts at the optic disc at about 16 weeks of 
gestation by vasculogenesis and then proceeds to reach nasal ora serrata at about 36 
weeks of GA and temporal ora serrata at about 40 weeks of GA by angiogenesis.
22-26
 
Vascular development of retina is by angiogenesis, arteriogenesis and vascularisation. 
Angiogenesis  – Endothelial lined blood vessel formation 
Arteriogenesis – Smooth muscle cells are added to endothelial cells to produce 
intact arterioles. 
Vascularisation – New arterialization of a tissue. Combination of these three is 
termed vasculogenesis. 
7 
 
Vasculogenesis is the denovo development of normal vasculature, involves the 
proliferation, differentiation, and organization of angioblasts. Circulating angioblasts in 
the area surrounding the optic nerve develops early retinal vessels.
27,28
 
 
Vessels reach nasal ora serrata first because nasal ora serrata is shorter distance 
from disc compared to temporal ora serrata. 
Before 28 weeks GA, outer segments of photoreceptors are not active, so 
metabolic demand of the retina is less and hence need for nutrition is low. At this time, 
entire retina is supplied by diffusion from choroidal circulation and development of 
choroidal vasculature completes by 22 weeks of gestation.  
At 28-32 weeks, vision begins and photoreceptor activates, metabolic demand 
increases and need for more blood supply but little change occurs in the choroidal 
vasculature. As a result of this, retina needs its own vascular supply to meet its metabolic 
demands.
29-32
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Retinal vascular development occurs in a relatively hypoxic environment in uterus 
where average PaO2 is 25-35mmHg, supported by fetal haemoglobin and lower metabolic 
demands. 
The retinal vasculature comprises two laminar layers, the primary superficial layer 
and ganglion cell layer in deeper retina which are interconnected by fine capillaries.
37
 
The formation of the primary vascular layer in the retina is associated with 
development of cells (astrocytes) in the nerve fibre region. 
Astrocytes are glial cells that provides biochemical support to endothelial cells, 
helps to sense physiologic hypoxia and express VEGF. 
VEGF is one of the important factors in vascular development and is associated 
with pathological angiogenesis. It creates a chemotactic gradient in extension of retinal 
angiogenesis to the peripheral ora serrata. 
From the optic nerve astrocytes emerge and they migrate just ahead of the 
developing vasculature. 
Astrocytes are present only in retina where retinal vasculature forms, and are 
restricted to the inner layer of retina that allows them to respond to hypoxia of the inner 
layers by expressing VEGF which is essential to induce the formation of the superficial 
layer of blood vessels. 
9 
 
Hyperoxia inhibits the formation of new blood vessel by down-regulating the 
VEGF expression of astrocyte. This down regulation may lead to a delay in the natural 
vascular development of retina. 
Insulin like growth factor(IGF-1) is another important factor in retinal vascular 
development. IGF-1 through control of VEGF activation regulates the retinal vascular 
development.  
Several studies showed the permissive role of IGF-1 in development of new blood 
vessel through control of VEGF activation.  
Low levels of IGF-1 retards the vessel growth despite the presence of VEGF. 
Fetus gets IGF-1 from placenta and amniotic fluid.
33-36
 
PATHOGENESIS OF ROP 
When an infant is born prematurely, the retinal vascular development must occur 
in an altered environment, thereby creating the risk for development of ROP.  
PHASES OF ROP:
38 
Phase 1: hyperoxia-vasocessation phase. 
From birth to 30-32 weeks of postmenstrual age (PMA). It is associated with 
apparent delay in regression of hyaloidal circulation.  
The infant’s retina become hyperoxic (even in room air), leads to decline in VEGF 
level and vasculogenesis is stopped for a time at the junction of vascular retina and 
10 
 
avascular retina, thereby raising the risk for ROP development. Hyperoxia causes VEGF 
down regulation that leads to death of the endothelial cells.  
Loss of newly developed capillaries will occur particularly if the infant was 
exposed to high oxygen at birth. Fluctuation in blood oxygen levels causes variation in 
concentration of VEGF, which is downregulated in hyperoxia and increased during 
hypoxia. Fluctuation in oxygen also leads to increased oxidative compounds, has a role in 
pathogenesis of ROP.  
IGF-1, erythropoietin and other cytokines are altered by premature birth and 
change in environment can have a role in the delay of physiologic vascular growth of 
retina. Due to loss of IGF-1 provided by amniotic fluid and placenta, its level falls after 
birth and is also suppressed by poor nutrition and sepsis. 
Preterm babies with prolonged “low serum IGF-1”and “poor postnatal weight 
gain” have high risk of ROP development. VEGF activation is suppressed by low IGF-1 
level thereby decreasing the growth of retinal vasculature. 
 
11 
 
Phase 2: relative hypoxia - revascularisation phase. 
 Starts at around 32-34 weeks of PMA. Before 32 weeks of gestation, 
photoreceptors are not yet fully functional and metabolic demand of retina is low. As the 
retina matures, there is increase in metabolic demand and oxygen consumption creating a 
state of relative retinal hypoxia.  
This increases the level of pro-angiogenic growth factors such as VEGF and 
erythropoietin leading to disordered growth of vessels into the vitreous. Overtime, 
postnatal levels of IGF-1 recover and reach a critical threshold, and triggering VEGF 
induced angiogenesis leading to development of ROP. 
Phase 2 ROP does not proceed with a gradual transition from avascular to vascular 
retina, rather a demarcated ridge develops between the central vascularised and peripheral 
avascular retina. Histologically, this structure consists of mesenchymal and endothelial 
cells. 
From this stage retinal vascular development may resume without significant 
disruption, or may lead to abnormal proliferation of retinal vessels into vitreous. 
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NATURAL HISTORY OF ROP 
 There occurs two forms of ROP. First is acute form followed by cicatricial or 
scarring/involutional forms.  
Acute disease - between 30 and 45 weeks of PMA.  
Cicatricial disease – starts as early as near term and continues for months post 
term. 
Normal pattern of retinal vascularization was given by CRYO-ROP and LIGHT-
ROP studies. Figure shows the zone III retinal vascularisation onset in no ROP babies. 
The two studies showed identical curves. 
  
 
Vascularisation of nasal retina : 
 median age - 35 weeks of PMA 
 onset range - 31 to40 weeks of PMA.  
 
13 
 
The natural history of ROP gives details about risk factors, onset and progression 
and prognostic factors of ROP and is given by three multicenter trials i.e “CRYO-ROP 
study, LIGHT-ROP study and ET-ROP study”. This includes infant specific data and 
retina specific data.  
Infant specific data- BW, GA, gender, race, and multiple births.  
Retina specific data - time of disease onset, stage, location, presence of plus 
disease, rate of progression as well as normal retinal vascularisation patterns.  
Incidence and severity of ROP is determined by GA and BW of infant specific 
data i.e. ROP incidence and severity increases with decreasing GA and BW.  
In development of any stage of ROP, race did not seem to be a factor but it has a 
role in the severe ROP incidence. Compared to white, black infants had less incidence of 
plus disease, prethreshold ROP and threshold ROP.  
No difference in ROP incidence between males and females, but somewhat higher 
risk was found in multiple birth infants.  
In 1991, from CRYO-ROP study, the most dramatic single natural history 
assessment was made by correlating prethreshold and threshold ROP onset with 
chronological age (CA) and postmenstrual age (PMA).
20
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Graphical representation of onset of “prethreshold ROP” by BW and CA.20 
 
 
Graphical representation of onset of “threshold ROP” by BW and CA.20 
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Graphical representation of onset of “prethreshold ROP” by BW and PMA.20 
 
 
Graphical representation of onset of “threshold ROP” by BW and PMA.20 
 
 
16 
 
Babies has been divided into birth weight quartiles in CRYO-ROP study as 1,000–
1,250 g, 750–1,000 g, and less than 750. They found that the smallest and most  
premature babies had longer time duration with the longer period of environmental 
exposure to develop severe ROP from birth, which has notable role in ROP screening. 
STUDIES MEDIAN ONSET OF 
PRETHRESHOLD ROP (PMA) 
CRYO-ROP study 36.1 weeks 
ET-ROP study 36.1weeks 
 
The “CRYO-ROP” study 39,40 found, 
Major prognostic indicators: 
ROP status,  
The location by zone in which ROP develops, and  
The presence of plus disease,  
Minor prognostic indicators: 
The circumferential extent of stage 3 disease, and  
More difficult to assess rate of progression.  
ET-ROP study confirmed the major importance of zone and plus disease. 
However, extent of stage 3 ROP by clock hours was not confirmed as an independent 
parameter in these studies. Presence of normal vascularisation in zone III and ROP in 
zone III has favourable prognosis but when zone II ROP is followed by zone III ROP 
negates this favorable prognosis.
41
 
17 
 
RISK FACTORS OF ROP
 
 Although many causative factors for development of ROP have been proposed, 
however low BW, low GA at birth and O2 supplementation have been consistently 
associated with ROP. 
Role of oxygen: The significance of oxygen levels in development of ROP lies 
with choroidal circulation, in that it fails to autoregulate in response to altered O2 tension. 
So in hyperoxic states, these vessels cannot constrict although the vessels of retina can 
constrict. As a result of this, movement of excess oxygen occurs from choroidal to retinal 
circulation which leads to constriction of retinal vessels to the point of obliteration. 
Alternative theory, damage produced by reactive O2 species particularly 
superoxide dismutase may outweigh the available defence mechanisms in the form of 
antioxidant enzymes such as α-tocopherol. 
Hyperoxic states also interfere with spindle cell growth and maturation, leading to 
break in normal migration and retinal vasculogenesis. Chronic anaemia in mothers is 
found to be protective factor for development ROP in babies exposed to O2 therapy in 
some studies. 
Studies have demonstrated that continued supplementation of O2 to babies who 
have developed “moderate ROP” does not decrease the ROP incidence, progression to 
“threshold ROP”, although it was found that wide fluctuations in O2 saturation levels may 
affect the development of ROP and progression.
42-44 
18 
 
Today’s modern neonatal intensive care units measures the oxygen saturation level 
and keeps it in controlled fashion thereby eliminating this risk.  
Role of genetic factors: In the early 1990s, the hypothesis put forwarded was 
genetic factors may also influence the ROP development and was suggested by the 
variation noted between different ethnic groups.  
This racial variation supports the role of genetic, socioeconomic or dietary factors 
in ROP development. 
Recent clinical and experimental studies in monozygotic twins with genetic 
approach showed that, there exists a strong genetic predisposition for the development of 
ROP.
45,46
 Studies showed three genes (Norrin, Frizzled 4, Lrp5) in Wnt signaling 
molecular pathways for development were mutated in some cases of advanced stage of 
ROP.
47-49 
This explains the progression to severe stage of ROP occurs in some babies 
even with timely intervention whereas spontaneous regression occurs in other babies with 
similar ROP. 
Multivariate analyses identified the following as independent risk factors for the 
ROP development.
38 
 low IGF-1,  
 poor postnatal weight gain,  
 hyperglycemia,  
 blood transfusions,  
19 
 
 surfactant therapy and  
 artificial ventilation for more than 7 days. 
Other risk factors include 
 systemic infections 
 intraventricular hemorrhage 
 bronchopulmonary dysplasia 
 patent ductus arteriosus. 
 
ROP SCREENING AND PREDICTION 
Primary goal of ROP screening – identifying the disease at a stage appropriate for 
intervention.  
Treatment window of opportunity - disease should be identified at a stage where 
treatment is needed but not beyond where treatment would be effective.  
ROP screening is a misnomer because it is the professional eye examination by an 
Ophthalmologist and must be no false negatives unlike in other disease screening which 
was conducted by non-physicians like screening of vision and laboratory screening blood 
tests. 
Screening the preterm infants who are at risk of developing ROP at right time 
helps in early treatment of severe ROP with good visual outcome. 
20 
 
Screening protocol for ROP is given by National Neonatology Forum (NNF) and 
it includes  
 All preterm neonates born < 34 weeks gestation and/or 
 All preterm neonates with < 1750 grams BW and  
 Babies born 34-36 weeks gestation or 1750-2000 grams BW along with the 
presence of risk factors for ROP (cardiorespiratory support, Respiratory 
distress syndrome, prolonged oxygen requirement, fetal haemorrhage, 
chronic lung disease, sepsis, blood transfusion, apnoea, intraventricular 
haemorrhage) are to be screened. 
 The first ROP screening retinal examination should be done not later than 4 
weeks of age in babies born ≥ 28 weeks of GA and early, by 2-3 weeks of 
age in babies born < 28 weeks of GA or < 1200 grams BW for early 
identification of AP-ROP.  
But, only 8% screened infants require treatment for severe ROP with current 
screening protocol. This shows that, current screening protocol needs modification. 
Formulation of easier and effective screening tool which predicts the development 
of “severe ROP” helps in identification of high risk babies and reduces unnecessary 
stressful examinations to no/low risk babies. 
Several studies suggest that poor weight gain and low serum IGF-1 in early 
postnatal period is strongly correlated with development of severe ROP later and also 
predicts the development of severe ROP.
50,51
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The role of IGF-1 in prediction of ROP was confirmed in several studies. Study by 
Pérez-Muñuzuri et. al. found that serum IGF-1 at three week post-partum in 74 preterm 
infant of Spanish population have a 90% sensitivity in prediction of ROP independent of 
GA at birth.
52 
In study by Pieh et. al,  42 preterm infants were assessed for plasma sE-selectin 
levels, 2 to 3 weeks after birth and found to be significantly increased in ROP patients 
suggesting it as a predictor for ROP.
53 
 
“Follow up examination schedule based on retinal findings: 
Zone I:  
Immature retinal vascularisation  – 1-2 weeks follow up 
 Stage 1 or 2     – 1 week or less follow up 
 Regressing ROP   – 1-2 weeks follow up 
Zone II:  
Immature retinal vascularisation  – 2-3 weeks follow up 
 Stage 1     – 2 weeks follow up 
 Stage 2     – 1-2 weeks follow up 
 Stage 3     – 1 week or less follow up 
 Regressing ROP    – 1-2 weeks follow up 
Zone III:  
Stage 1 or 2     – 2-3 weeks follow up 
 Regressing ROP    – 1-2 weeks follow up” 
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“ET-ROP protocol for treatment includes, 
Type 1 ROP called new threshold, treatment is peripheral retinal ablation includes 
Zone II: stage 2 or 3 with plus disease 
Zone I : stage 1, 2, or 3 with plus disease 
Zone I : stage 3 without plus disease 
Type 2 ROP called low risk prethreshold ROP, wait and watch for progression includes 
Zone II: stage 3 without plus disease 
Zone I : stage 1 or 2 without plus disease” 
AP-ROP requires ablative laser therapy, stage 4 or stage 5 ROP requires       
vitreo-retinal surgical intervention.  
DISCONTINUING SCREENING 
Unless eyes have been treated (laser and/or anti-VEGF) for severe form of ROP, 
treating ophthalmologist can discontinue ROP screening examination if any of the 
following criteria are met.
38 
 Full retinal vascularisation 
 Zone III retinal vascularisation without previous zone I or zone II ROP 
 Lack of development of worse or prethreshold ROP by 50 weeks of PMA
 Regressing ROP in zone III without abnormal vascular tissue, which is capable of 
reactivation in zone II or zone III. 
 Ultimately, decision must be tailored to individual’s disease course. 
23 
 
CLASSIFICATION OF ROP 
54,55 
The International Classification for Retinopathy of Prematurity (ICROP) provides 
standards that promote collaborative clinical investigations and was updated in 2005 to 
reflect our modern understanding of ROP features. 
The parameters used in ICROP: 
Zone,  
Stage (extent of the stage of ROP is no longer used in describing the severity) and  
Presence of plus disease.  
ZONES OF RETINOPATHY OF PREMATURITY:  
 
Zone I - circle centered on optic disc whose radius is double the distance from the 
optic disc to the foveal center. It subtends an arc of about 60 degree.  
24 
 
A clinical correlate for estimating the temporal extent of zone I is to place the 
nasal margin of optic disc in the field of view of a 28D lens, with the limit of zone I being 
the temporal field of view.  
Zone II - circle peripheral to zone I with a radius from optic nerve to nasal ora 
serrata. Temporal boundary corresponds approximately to the anatomic equator. 
Zone III - remaining temporal crescent of retina anterior to zone II, is the last to 
become vascularised. 
STAGES OF RETINOPATHY OF PREMATURITY 
Based on  
 “Location of retinal involvement 
   Extent of involvement by clock hour 
  Stage of the disease at the junction of vascular and avascular retina” 
Vascular stages i.e stages 1-3, defined by 
 appearance noted at the junction of vascular and avascular retina. 
Fibrovascular stages i.e stages 4 and 5, defined by presence of 
 vitreous traction and fibrovascular membranes 
 area of retinal detachment and macular involvement 
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STAGE 1 – “DEMARCATION LINE” 
First visible sign of ROP using ophthalmoscope. 
Appearance - flat and white structure between avascular and vascular retina.  
Lies within the retinal plane.  
Abnormal arcading of vessels can lead up to the line.  
It either progress to ROP stage 2 or involutes to normal vascularisation.  
According to Garner,
56
 it has two relatively distinct zones morphologically, 
“vanguard, the anterior zone has spindle-shaped cell mass and these are considered to be 
progenitors of the differentiated vascular endothelium”. Hyperplasia of these makes the 
demarcation line visible ophthalmoscopically. 
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STAGE 2– “RIDGE” 
The demarcation line has become a ridge with height and width and extends 
centripetally within the globe.  
Ridge colour - white or pink  
Rarely vessels may leave the retinal surface to enter it.  
Posterior to the ridge structure small tufts of new vessels (“popcorn” lesions) may 
be seen but is not attached with the ridge.  
According to Garner,
56 it is due to endothelial cell proliferation “with some 
evidence of organization into recognizable vascular channels.” On fluorescein 
angiography these channels shows leakage.
57 
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STAGE 3 – “RIDGE WITH EXTRARETINAL FIBROVASCULAR 
PROLIFERATION” 
Extraretinal, fibrovascular tissue proliferation occurs from former ridge.  
It is localized and is continuous with posterior aspect of the ridge, giving a ragged 
appearance to it, with increase in proliferation into the vitreous.  
Depending on the amount of proliferative tissue it is subdivided into 3 stages- 
mild, moderate and severe.  
According to Foos, appearance of extraretinal vascularisation on histological 
examination may be placoid, polypoid, or pedunculated.
58
 
The most common and important is placoid, because this pattern can progress to 
retinal detachment.  
  
 
According to Foos, “extraretinal vessels are derived from proliferating endothelial 
cells and not from the mesenchymal spindle cells”, vitreous changes are synchysis and 
condensation.
66
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RETINAL DETACHMENT 
Most common form observed in acute ROP is tractional retinal detachment. It 
originates at the ridge, at which point there is a pull of myofibroblast centripetally 
towards the lens in purse-string configuration.  
Peripheral detachment which occurs posterior to the ridge can proceed to total 
detachment in a week. At this stage peripheral retinal cryoablation appears to reduce by 
half the incidence of childhood RD. 
 Exudative retinal detachment occur less commonly in acute ROP. This occurs as 
result of plasma leakage from abnormal neovascular tufts and leads to sub retinal fluid 
accumulation. 
 Sometimes chronic vitreoretinal traction has a role in exudation. Retinal findings 
are smooth retinal detachment with yellow exudates; small angioma with retinal 
haemorrhage can be seen. Sometimes intravitreal anti-VEGF can be used in this 
condition.  
Rhegmatogenous retinal detachment occur very rarely. 
STAGE 4 –PARTIAL RETINAL DETACHMENT58-60 
STAGE 4A: “EXTRAFOVEAL RETINAL DETACHMENT” 
Concave, traction detachment of the peripheral retina without involving macula 
and occur at the site of extraretinal fibrovascular proliferation with vitreous traction. It 
may be segmental or circumferential for 360 degree. In the absence of posterior extension 
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prognosis is relatively good. Spontaneous reattachment may occur without affecting 
macular function. 
 
  
 
        
 
STAGE 4B: “PARTIAL RETINAL DETACHMENT INVOLVING THE FOVEA” 
Partial retinal detachment as a result of fibrovascular proliferation involving the 
macula and visual prognosis is poor because of macular involvement.  
 
 
BOTH EXUDATIVE AND 
TRACTIONAL 
 
EXUDATIVE TYPE 
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STAGE 5: “TOTAL RETINAL DETACHMENT” 
It is usually funnel-shaped and classified as “open” or “closed” anteriorly or posteriorly 
based on shape of the funnel. 
 First common type - concave configuration and is open anteriorly and posteriorly 
and extends upto disc. 
 second type - funnel is narrow anteriorly and posteriorly.  
 Third type- funnel is open anteriorly and narrow posteriorly. 
 Fourth least type - funnel is narrow anteriorly and open posteriorly. 
These configurations are detected by ultrasonography. Sometimes adherence of detached 
retina to posterior lens capsule may be seen.  
 
 
  
 
 
 
OPEN FUNNEL RD CLOSED FUNNEL RD 
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“PLUS” AND “PRE-PLUS” DISEASE 
“Plus disease” - “dilatation and tortuosity of retinal arteries and veins in the 
posterior pole” and is indicator of poor outcome.61 It is associated with pupillary rigidity, 
iris vascular engorgement and vitreous haze. CRYO-ROP trial introduced standard 
photographs as the minimum abnormality necessary for plus disease diagnosis.
62 
Plus disease is postulated to occur either by shunting of blood through the 
neovascular ridge or as a response to increased VEGF acting on the blood vessels 
themselves. 
Revised ICROP guidelines defined “preplus disease” – “dilatation and tortuosity 
of posterior pole vessels that is insufficient to diagnosis as plus disease”. 
 
 
   
 
 
 
PLUS DISEASE PLUS DISEASE 
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AGGRESSIVE POSTERIOR ROP 
Used to describe posterior disease (zone I or posterior zone II) 
Characterized by dramatic plus disease that appears out of proportion to extent of 
retinopathy.  
It progresses to retinal detachment without evolution through the classic stages. 
It can have circumferential vessels at the junction of vascular and avascular retina, 
and also flat neovascularisation. 
 
 
INVOLUTION OF RETINOPATHY OF PREMATURITY 
“Involution of ROP”- downgrading of ROP stage and/or growth of retinal 
vasculature into a more peripheral zone and it begins after 38 weeks of PMA.
64 
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RETINAL FINDINGS OF “REGRESSED ROP” 
Residual changes of regressed ROP
65,66 
is classified as, 
 Retinal periphery changes and  
 Posterior fundus changes 
Peripheral and posterior changes are further classified into vascular and retinal changes.  
Peripheral vascular changes are 
 Failure to vascularise peripheral retina 
 Vascular arcades with circumferential interconnection 
 Abnormal, non-dichotomous branching of retinal vessels 
 Telangiectatic vessels 
Peripheral retinal changes are 
 Pigmentary changes 
 Lattice-like degeneration and retinal breaks 
 Traction or rhegmatogenous RD 
Posterior Vascular changes are 
 Vascular tortuosity 
 Abnormality in the angle of insertion of major temporal arcade 
 Blood vessels get straightened in temporal arcade 
Posterior Retinal changes are 
 Pigmentary changes 
 Dragging of retina over disc 
 Distortion and ectopia of macula. 
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OCULAR FINDINGS OF “REGRESSED ROP” 
 Myopia,57 
 Astigmatism, anisometropia ,68 
 Amblyopia,  
 Strabismus, nystagmus,  
 Glaucoma. 
 Lens changes - cataract,69 
 Corneal changes - band keratopathy, corneal curvature irregularities and acute 
hydrops.
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CICATRICIAL DISEASE 
20% of infants with active ROP develop cicatricial complication from mild to 
extremely severe form.
65,66
 More advanced and more posterior to the proliferative disease 
at the time of involution develop worse cicatricial sequalae. 
Stage 1: Pigmentary changes in peripheral retina and vitreous base haze. 
Stage 2: Vitreoretinal fibrosis and straightening of temporal vascular arcades follows 
dragging of macula and disc. 
Stage 3: Severe fibrosis of peripheral retina with contracture and falciform retinal fold. 
Stage 4: Incomplete ring of retrolental fibrovascular tissue with total RD called as 
retrolental fibroplasias occur.  Progressive shallowing of anterior chamber is caused by 
forward movement of iris-lens diaphragm and development of anterior synechiae and 
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secondary angle closure glaucoma. Lensectomy and anterior vitrectomy can be tried but 
results are poor. 
Cicatricial macular changes classification:
70 “
MS – Macular score” 
“MS-0 Normal 
  MS-1 Macular ectopia 
 MS-2 Macular fold 
 MS-3 Macular detachment 
 MS-4 Total detachment” 
 
   
 
 
 
 
MACULAR HETEROTOPIA MACULAR FOLD 
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DIFFERENTIAL DIAGNOSIS 
1. FAMILIAL EXUDATIVE VITREORETINOPATHY 
This condition associated with neovascular disease may be indistinguishable from 
acute ROP. It resembles changes seen in stage 1 to 3 ROP. 
Differentiating feature is no history of prematurity, positive family history, 
asymmetry in both eyes. Changes in familial exudative retinopathy may be detected 
anytime from birth to ten years of age. 
2. RETINOBLASTOMA  
It is also one of the differential diagnosis of stage 5 ROP and differentiation is 
based on the history of prematurity, asymmetrical presentation. Ultrasonography 
confirms the diagnosis. 
 It shows posterior mass lesion with calcification. In contrast, ultrasonography in 
ROP shows complex pattern of multiple echoes behind the lens or retinal detachment. 
3. PERSISTENT HYPERPLASTIC PRIMARY VITREOUS (PHPV) 
It is a congenital anomaly that occurs in term infants. Unilateral condition 
associated with microcornea, greyish white membrane behind the lens which has to be 
differentiated from ROP. Vessels are seen behind the lens in retinal detachment of ROP. 
In PHPV, retina is usually attached and stalk extends from optic disc to posterior lens 
surface. 
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4. COAT’S DISEASE 
 It arises from abnormal telangiectatic retinal vessels. Features are retinal edema 
due to profuse leakage from telangiectatic vessel, yellow-green subretinal material and 
exudative detachment. Leucocoria is the initial presentation of these cases. 
5. NORRIE’S DISEASE  
 It is X-linked disorder presenting with leucocoria, deafness and mental retardation. 
Examination at 4-6 weeks of age presenting with leucocoria is confused with ROP. 
Leucocoria in ROP present in very late stage due to stage 5 ROP. 
5. INCONTINENTIA PIGMENTI 
Multisystem disorder affecting females. It has dermatological, dental and 
neurological findings. Ocular features include preretinal neovascularisation, peripheral 
retinal vascular nonperfusion, vitreous haemorrhage and tractional retinal detachment. 
Term at birth and characteristic vesicobullous lesion differentiates from ROP. 
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PREVENTION
 
Best treatment for ROP will be prevention. 
 By addressing the strategies to decrease the incidence of premature birth and low 
birth weight, it is possible to prevent ROP.   
Reducing high risk pregnancies, better prenatal care thereby prolonging gestation 
and promoting the avoidance of illegal drug use helps to reduce the incidence of ROP. 
Several studies were conducted and ongoing to address the strategies to prevent 
the development of “severe ROP”.  
In the 1990s the “STOP-ROP study”71, a multicetre trial was conducted with goal 
of eliminating the hypoxic stimulus for new vessel formation.  
In this trial, 694 infants with prethreshold ROP were assigned in a random manner 
to maintain O2 saturation levels of 96%-99% in supplemental group versus 89%-94% in 
conventional group.  
Result showed no statistical difference between the two groups (41% versus 48%) 
in rate of threshold ROP progression. 
In the subgroup of infants with prethreshold ROP without plus disease, a post hoc 
analysis was done and result showed progression to threshold  ROP in the supplemental 
arm was significantly reduced (32% versus 46%).  
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Of concern is that adverse pulmonary events and increased duration of hospital 
stay occurred more frequently in the supplement group. Several studies demonstrated the 
beneficial role of carefully regulating the oxygen saturation levels within specific limits.  
Studies from 2003 to 2006 demonstrated significant decrease in prethreshold 
disease and “severe ROP” after institution of criteria to maintain oxygen saturation 
between 85%-93%.  
However, some studies showed increased mortality even though the severity of 
ROP was reduced if oxygen saturation target maintained between 85%-89%. 
The LIGHT–ROP trial was conducted to test the hypothesis that reduced 
extrauterine light using light–blocking goggles from birth to 31 weeks of 
postconceptional age would decrease the ROP incidence but found no clinical or 
statistical difference between treatment and control groups.
72
 
Recent experimental evidence suggested that in late gestation, exposure to greater 
light may be a factor in hyaloidal regression and retinal vascular development.  
Studies conducted to test antioxidants including vitamin E and D-penicillamine 
showed mixed results.
73 
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RET CAM II 
Ret cam II was current technique of screening for retinopathy of prematurity
74
. As 
the number of premature babies is rising, Ret cam becomes easy to screen the premature 
infants. Ret cam images are clear and reliable.  
Portability and the features of Ret cam made it tool for diagnosis and teaching 
purpose. Ret cam II consists of contact retinal camera which is placed over the cornea 
with the help of coupling fluid. 
 Choice of lenses available is 30, 80, 120, 130 degrees and portrait. Wide field 
image is captured and it is converted into digital, high resolution colour photograph. 
TREATMENT 
Aim of the ROP treatment is maximal preservation of neurosensory retinal 
structure and function with minimal complications. Clinical studies found that peripheral 
diode laser photocoagulation is superior to cryotherapy in treatment of ROP.
75,76
 
Current treatment guidelines are based on clinical trials that attempted to define 
the mildest form of the disease for which the benefit of treatment would outweigh its risk 
and lead to improved anatomical and visual acuity outcomes. 
Cryotherapy was used in the treatment of ROP since 1972. The CRYO–ROP study 
included 291 infants with “threshold ROP” and they were randomized to either 
cryotherapy within 72 hours or observation.  
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“Threshold ROP was defined as 5 contiguous or 8 cumulative clock hours of stage 
3 ROP and plus disease in zone I or zone II” and the estimated risk of progression to an 
unfavourable outcome was 50%.  
The 10-year result of the CRYO-ROP study showed that for untreated eyes with 
zone II threshold disease, 62% had a poor visual outcome. However for zone I threshold 
ROP, 87% had poor visual outcome.  
Because of significant decrease in unfavourable outcomes such as posterior retinal 
folds, retinal detachment, or development of retrolental tissue in the treatment group 
(31% treated versus 51% observed), the CRYO-ROP study was terminated early. 254 
infants were followed for fifteen-years which demonstrated the long-term benefits of 
treatment. 
 There was also a decreased incidence of poor visual acuity in treated eyes. (45% 
treated versus 64% observed).
77 
Availability of indirect laser photocoagulation was not widely available at the time 
of the CRYO-ROP study.  
However, in the study the favourable outcome were presumed to be due to the 
ablation effect on the peripheral avascular retina and it was extrapolated to be similar if 
laser were used.  
Some studies demonstrated that laser treated eyes had better structural and 
functional outcomes compared to cryotherapy treated eyes. 
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Later a study was conducted to determine whether early treatment of ROP would 
result in better outcomes.  
In ETROP study, eyes at risk of developing “threshold ROP” was defined as 
“prethreshold ROP” and it was further subdivided into type1 ROP, in which there was 
≥15% chance of unfavourable outcome based on eye and infant characteristics from the 
CRYO-ROP and type 2 ROP, in which <15% chance of unfavourable outcome. 
ETROP finding demonstrated that type 1 ROP benefited with peripheral laser 
ablative treatment to the avascular retina and type 2 ROP observation twice-weekly until 
the disease either progressed to a higher-risk category or improved.  
At the end of 9 months, result showed that in the earlier treatment group 
unfavourable visual outcomes were reduced to 14.5% when compared to 19.5% in the 
conventional group (treatment for threshold disease). Both of these results were 
statistically significant.  
Follow up at the end of 6 years showed fewer unfavourable structural outcomes in 
early treated eyes. Visual acuity outcomes were not statistically significant at 6 years; 
but, subgroup analysis demonstrated improved visual acuity for eyes with zone I in the 
early treatment group.
78 
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CURRENT GUIDELINES RECOMMENDED INITIATING TREATMENT OF 
SEVERE ROP WHEN CRITERIA FOR TYPE 1 ROP ARE MET. 
If type 1 ROP develops, ablation of avascular retina by laser photocoagulation 
should be performed within 72 hours based on the ETROP protocol.
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From the ora serrata upto the avascular retina but not including the ridge for 360 
degree, grey to grey white burns spaced one-half laser burn width.  
Systemically, infants are at risk of bradycardia, apnoea and cardiopulmonary arrest 
during or following treatment and must be followed closely.  
Ocular complications are rare but include misplacement of laser burns, post laser 
inflammation, cataract, vitreous hemorrhage, glaucoma secondary to anterior rotation of 
the lens-iris diaphragm, and extremely rarely, pthisis bulbi.  
Topical steroids and cycloplegics are given for a short time after treatment. 
Treated eyes are followed within 3-7 days and then weekly or more frequently.  
Persistent or recurrent disease is treated with further laser and vitreoretinal surgery 
is considered for progressive stage 4 ROP. 
The “BEAT-ROP” study (“Bevacizumab Eliminates the Angiogenic Threat of 
Retinopathy of Prematurity”) tested bevacizumab (anti-VEGF antibody), given 
intravitreally at 0.625 mg in 0.025 ml in 150 infants.
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It benefited the babies with zone I stage 3+ ROP.  
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This study was too small to assess the effects of bevacizumab on development of 
brain and other tissues, and did not address drug dosage and is also not FDA approved 
drug for ROP treatment. Bevacizumab is used only for zone I stage 3+ROP after getting 
detailed informed consent.  
Following treatment, examinations are done weekly until complete vascularisation 
of the retina. Follow up exams must be done for a longer period than after conventional 
laser ablation treatment, because recurrent stage 3 ROP can occur at later time than after 
conventional laser treatment. Assure follow up after bevacizumab treatment particularly 
after discharge or transfer from a neonatal unit.
80,81 
LASER PHOTOCOAGULATION 
 Ablation of ischemic avascular retina stops the release of angiogenic factors and 
this forms the basic principle of management. 
 
 Advantage  
 Treatment of more posteriorly located disease, where cryoprobe is not accessible. 
 Good structural and functional outcome 
 No need for general anaesthesia 
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 Procedure  
Written informed consent from parents or legal guardian should be obtained 
Nature of disease, disease progression, complication and long term sequelae to be 
explained to the parents 
Retreatment, surgical intervention and long term follow up also to be explained 
Feeds to be deferred at least half an hour prior to the treatment. 
Neonatologists and anaesthetist should be there during the procedure 
Pupillary dilatation to be adequate 
In case of incubator dependant infants, procedure to be done in incubator with 
sloping walls 
Portable infra-red diode laser, frequency doubled Nd: YAG laser or an argon laser 
can be used 
Laser indirect ophthalmoscope delivers the laser. Diode laser is used worldwide for 
treatment as it penetrates the eyes with tunica vasculosa lentis and vitreous 
haemorrhage 
Paediatric lid speculum applied, with wire vectis or scleral depressor indentation is 
done. 
Using  20 or 28 D aspheric lens visualisation of the retina is done 
Power of diode laser varies from 300 to 400mw and the duration of laser is 300 to 
400ms. 
Laser settings should be kept minimum to produce light grey burns 
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Ablation of entire avascular retina from ridge to ora in near confluent burn pattern 
to be done 
Less than half burn width should be as getting close to edge of the ridge. 
Confluent treatment has less progression compared to dense laser treatment. 
Laser spots are delivered in areas enclosed by flat neovascular loops as in case of 
aggressive ROP 
Mechanical pupillary dilatation can be done in case of poor dilatation of pupil due 
to tunica vasculosa lentis. 
Carboxymethyl cellulose topically provides the clear view of cornea during the 
procedure. 
Antibiotic -steroid eye drops  to be instilled for 1week to control inflammation 
Some premature infants develop apnoea during laser treatment and they need 
resuscitation and ventilator support. 
 
 
    
 
 
BEFORE LASER 
TREATMENT 
AFTER LASER 
TREATMENT 
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Conjunctival chemosis and subconjunctival haemorrhage may develop in case of 
excessive scleral indentation. 
Preretinal and vitreous haemorrhage rarely occur 
Intense photocoagulation sometime cause anterior segment ischemia and necrosis 
Follow up 
 Follow up is usually done at 1week. Response is assessed by 
 Extent of plus disease 
 Presence of skip areas  
 Status of ridge and fibrovascular proliferation 
 Vitreous organization  
 Presence or absence of vitreous haemorrhage 
 Tunica vasculosa lentis 
 Additional laser, in case of significant plus disease with skip areas are still present. 
Plus disease without skip areas, to be followed weekly interval. Follow up should be done 
till the regression of ROP occurs. 
 If there is no fibrovascular proliferation baby should be followed upto 6months of 
age.  
 In case of significant fibrovascular proliferation close follow up at weekly interval 
for tractional retinal detachment should be done. 
SURGICAL MANAGEMENT-RETINAL DETACHMENT
82-84 
According to ETROP study sixteen percent of patients with type 1 ROP had 
retinal detachment in at least 1 eye.  
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Of these, 38% of patients had bilateral retinal detachment. Half of the retinal 
detachments were in stage 4 and half were in stage 5. Classification of retinal detachment 
- effusive (serous), tractional (fibrovascular), and rhegmatogenous.  
Serous retinal detachment is believed to be caused by leakage from vascular 
structures into the retina and subretinal space and this type presents with convex shape, 
often posterior to the ridge, with extension towards the macula and lens.  
Tractional retinal detachment demonstrates fibrovascular tissue causing peaked 
retinal folds.  
Serous stage 4 ROP often resolves spontaneously, and observation or surgical 
intervention can be made appropriately on an individual basis. Retinal detachment can 
occur within 12 weeks of laser treatment in 14% of eyes received laser treatment.  
Treatment of advancing stage 4 ROP is lens-sparing vitrectomy to release 
fibrovascular traction and without creating any holes allow the retina to settle back 
spontaneously and is optimal to prevent progression to stage 5 ROP and preserve macular 
structure.  
Additionally, sclera buckling procedure can be done for treatment of advancing 
stage 4 ROP. 
For stage 5 ROP treatment options include vitrectomy with or without sclera  
buckle and only scleral buckle.  
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In aphakia, visual rehabilitation is difficult and every attempt should be made to 
preserve the lens during vitrectomy procedure; however, even when a lens sparing 
vitrectomy is performed, in 5%-15% of cases cataract may occur. 
Poor outcomes for all interventions are associated with the presence of plus 
disease, persistent neovascularisation, and vitreous haze. Scleral buckling is associated 
with high myopia, anisometropia and amblyopia.  
OTHERS THERAPIES 
 Major angiogenic factors responsible for ROP pathogenesis is VEGF. VEGF levels 
in vitreous of babies with vasoproliferative ROP were assessed and found to be 
significantly elevated.
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 Studies in animal models showed suppression of neovascularisation with 
VEGF.
86,87 
In ROP several reports exist about the off-label use of bevacizumab as anti-
angiogenic therapy which was either used alone or in conjunction with laser treatment.  
 Lee et. al. studied 15 cases treated for ROP stage 3 with both intravitreal 
bevacizumab and laser ablation and noted regression of plus disease with rapid 
development of the peripheral retinal vasculature and also noted that no significant 
difference in systemic and ocular complications compared to laser therapy alone.
88 
In ROP treatment, considerable concerns remain as to the safety of anti-VEGF, 
especially regarding to “the time of injection, correct dosage and potential local 
complications such as lens damage, adverse effects on retinal neurosensory development, 
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infection and unknown systemic effects in children with already persistent subnormal 
growth, impaired cortical function” 
Therefore, randomized control trials are needed to establish the safety and efficacy 
of bevacizumab in ROP treatment before reliable statements can be made. 
Numerous research works in angiogenesis suggest a several new methods to 
interfere in the progression of ROP includes
 
 Targeting the IGF-1 pathway89,90 and  
 Supplementation of omega-3 polyunsaturated fatty acids in diet.  
Lack of IGF-1 prevents the development of normal retinal vasculature despite the 
presence of VEGF.  
After birth if IGF-I level is adequate, development of retinal vessels occur 
normally without development of ROP in premature babies.  
Persistently low IGF-I retards the retinal vessel growth, maturing avascular retina 
becomes increasingly hypoxic and leads to VEGF accumulation in vitreous.  
 These factors suggest that in premature infants IGF-I predict whether the baby will 
develop ROP or not.
91
 
 Early reinstitution of IGF-I in preterm babies may prevent the development of ROP. 
Study conducted in Sweden showed that combination of “IGF-I and IGF-binding protein 
3 complex” in preterm babies was safe.  
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Therefore, IGF-1 supplementation in ROP phase I would hypothetically normalize 
the retinal vascular development thereby preventing abnormal vascular proliferation in 
ROP phase II.   
A clinical trial is underway “to investigate the possibility of preventing ROP in 
preterm babies by restoring IGF-1 to the in utero levels”.92 
Recently in ROP animal model studies showed that pathologic neovascularisation 
is protected by dietary supplementation of omega-3 PUFAs. 
At present to treat severe cases of neovascular ROP, laser photocoagulation is the 
only well established treatment.  
VISUAL REHABILITATION 
Infants who developed ROP are more likely to develop high myopia, strabismus, 
amblyopia, macular heterotropia and glaucoma.  
Infants who are aphakic or have a sclera buckle in place require rehabilitation with 
special treatment for high refractive error. 
Babies with more severe form of ROP may not develop macular vision; however, 
spectacles can be given to improve the vision and provides protection against ocular 
trauma. 
 In an early intervention program, all visually impaired babies should be enrolled 
and that teaches them to fully utilize their impaired vision and other senses.  
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Infants with ROP may have other comorbidities that contribute to poor vision 
which include intraventricular hemorrhage, cerebral visual impairment, and 
hydrocephalus. 
MEDICOLEGAL CONSIDERATIONS 
Screening of premature infants for ROP and treatment is an essential aspect in the 
practice of ophthalmology. There are three aspects in ROP care which places the 
premature infant and the entire healthcare team at risk. 
First, premature babies who are at risk of ROP development typically have 
multiple medical consultants responsible for their care. Appropriate steps should be taken 
to ensure that treating ophthalmologists are kept aware of status and location of the 
babies they follow so that screening examinations are not missed. 
Second, parents of premature infants often feel overhelmed and effort should be 
needed to ensure compliance with screening, treatment and follow up at the appropriate 
intervals. 
Third, the treatment window for ROP is very short and treatment may require 
transfer of a critical patient. The entire team of neonatologists, ophthalmologists, and 
nurses become targets of ligitation when protocols for ROP care break down. 
Ophthalmologists who is doing ROP examination and treatment can optimize care for the 
babies and minimize their exposure to lawsuits by educating parents and documentation 
in the medical record. 
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AIMS AND OBJECTIVES 
To analyse the postnatal weight gain in babies with “no ROP”, “mild ROP” and in 
babies with “severe ROP”. 
To determine the role of weight gain in early postnatal period in predicting the 
development of severe ROP requiring treatment in preterm babies, in our hospital. 
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MATERIALS AND METHODS 
STUDY DESIGN: 
Prospective observational study 
STUDY PERIOD:  
 This study was conducted from March 2016 to August 2016 for a period 6 months. 
STUDY CENTRE: 
Department of Ophthalmology, Government Rajaji Hospital, Madurai. 
Institute of Paediatrics, Government Rajaji Hospital, Madurai. 
SAMPLE SIZE:  
 Total sample size was 100 babies fulfilling the eligibility criteria. 
ETHICAL APPROVAL: 
Institutional ethical clearance was obtained from the ethical committee, 
Government Rajaji Hospital, Madurai.  
INFORMED CONSENT: 
Informed written consent obtained from parent or guardian of all babies before 
enrollment.  
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SELECTION OF STUDY SUBJECTS: 
 100 babies fulfilling the eligibility criteria for ROP screening were selected from 
those attending ROP screening clinic in Eye department OPD and as inpatient in 
Neonatal Intensive Care Unit of Government Rajaji Hospital, Madurai. 
 
 INCLUSION CRITERIA: 
 Babies born less than 34 weeks gestation and or  
 Babies born with birth weight less than 1750 grams. 
EXCLUSION CRITERIA: 
 Babies with non-physiological weight gain includes 
 hydrocephalus,  
 congestive cardiac failure and  
 hydrops. 
 Babies with obvious congenital anomalies. 
 Babies expired before the completion of ROP screening.  
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METHODOLOGY: 
Parameters recorded were Infant’s birth weight, gestational age at birth, 
postconceptional age and other risk factors such as long term exposure to oxygen, 
mechanical ventilation, surfactant use, Respiratory Distress Syndrome, septicaemia, 
multiple blood transfusions, multiple births, apnoeic episodes and intraventricular 
haemorrhage. 
Gestational age calculated according to last menstrual period or first trimester 
abdomen sonogram. 
The screening examination for ROP followed in our study was based on guidelines 
proposed by NNF (National Neonatology Forum).  
The first retinal examination was performed at 4 to 5 weeks of age. 
Ocular examinations were carried out by binocular indirect ophthalmoscope with 
+20 D lens and findings were recorded in the ROP screening case sheet.  
Revised ICROP classification was used for categorization of ROP. Follow up 
examinations were based on the retinal findings and continued until complete 
vascularisation or regressing ROP was noted or until treated based on the ETROP 
guidelines. 
The main clinical outcome observed was occurrence of severe ROP requiring 
treatment. 
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In our study “mild ROP” was defined as ROP that does not meet criteria for 
treatment based on CRYO-ROP study and ETROP study guidelines and, “severe ROP” 
was defined as either Type 1 ROP based on ETROP study findings, threshold ROP, AP-
ROP, stage 4 or stage 5 ROP that needs treatment. 
Babies were divided into two groups. 
Group 1: Infants with no ROP and mild ROP.  
Group 2: Infants with severe ROP. 
WEIGHT MEASUREMENT: 
 Infants weighed unclothed before feed on calibrated electronic weighing 
machine with a digital read out. 
 Infant’s weight recorded weekly till 4th week and at 6th week of post natal age, 
and relative weight gain calculated for the same. 
 Relative weight gain calculated by body weight minus birth weight, divided by 
birth weight and chronological age, (g/kg/day).  
PROCEDURE: 
 Procedure explained to the parent/guardian. 
 The baby fed 1hour before examination. 
 Incubator dependant babies were screened within incubator itself. 
 Hands washed with 2% of chlorhexidine. 
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 Both eyes were dilated with combination of  tropicamide 0.8% and phenylephrine 
5% diluted in tear substitutes in 50:50 ratio, and used two to three times about 10-
15 minutes apart prior to examination. 
 Excess drops wiped off to avoid systemic absorption of drugs through cheek skin. 
 Baby placed in examining couch. 
 Drop of topical anaesthetic, 4%lignocaine was instilled into both eyes. 
 Paediatric eye speculum applied. 
 Retina examined using binocular indirect ophthalmoscope with + 20D lens and 
retinal periphery using scleral indentation. 
 
 First examination of anterior segment was done to look for the presence of tunica 
vasculosa lentis, pupillary dilatation and lens/media clarity. 
 Followed by posterior pole examination to look for the presence of “plus disease” 
and sequential examinations of all clock hours of peripheral retina. 
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STATISTICAL ANALYSIS 
The data were analysed with SPSS statistical software package (Version 16.0 
SPSS Inc., Chicago, USA ).  
The relative weight gain was calculated for second week, fourth week and sixth 
week of postnatal age and compared between “no ROP/mild ROP” group and “severe 
ROP” group using unpaired student ‘t’ test, P value of <0.05 will be considered as 
statistically significant. 
RESULTS 
The study was conducted in department of Ophthalmology and at Institute of 
Paediatrics in Government Rajaji Hospital, Madurai to analyse poor postnatal weight gain 
as a predictor for “severe ROP” requiring treatment. Totally 100 babies were recruited for 
the study after satisfying the inclusion and exclusion criteria. After obtaining informed 
consent from parents/guardians of babies, they were divided into two groups.  
Group 1: Infants with no ROP and mild ROP.  
Group 2: Infants with severe ROP.  
All the babies were followed until complete vascularisation of retina or regressing 
ROP or until treatment. 
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SEX DISTRIBUTION 
Among 100 babies analysed, 43 were males and 57 were females,  
Group 1 had 39 males and 52 females while Group 2 had 4 males and 5 females. 
TABLE 1 
 MALE FEMALE 
NO ROP/MILD ROP 39 52 
SEVERE ROP 4 5 
 
FIGURE 1  
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Among 100 babies, 88 were single gestation and 12 were twin gestation,        
Group 1 had 81 single gestation and 10 twin gestation babies and group 2 had 7 single 
gestation and 2 twin gestation babies.  
TABLE 2: 
 SINGLE TWIN 
NO ROP/MILD ROP 81 10 
SEVERE ROP 7 2 
 
FIGURE 2 
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GESTATIONAL AGE DISTRIBUTION 
 In group 1, mean gestational age at birth was 32.24±1.43 weeks ranged 
from 28-34 weeks. In group 2, mean gestational age at birth was 29.9±1.04 weeks ranged 
from 28-32 weeks. Two groups were compared using unpaired student ‘t’ test and found 
to be significant with P-value of <0.01. 
 TABLE 3 
GESTATIONAL AGE 
AT BIRTH 
≤30 WEEKS 31-32 WEEKS >32 WEEKS 
NO ROP/MILD ROP 11 36 44 
SEVERE ROP 7 2 0 
 
FIGURE 3 
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BIRTH WEIGHT DISTRIBUTION  
In group 1, mean birth weight was 1396.20±248.23 grams ranged from 1000-1750 
grams. In group 2, mean birth weight was 1164.44±140.99 grams ranged from 930-1300 
grams. Two groups were compared using unpaired student ‘t’ test and found to be 
significant with P-value of <0.01. 
TABLE 4 
BIRTH WEIGHT ≤1000 GRAMS 1001-1500 GRAMS >1500 GRAMS 
NO ROP/MILD ROP 11 55 25 
SEVERE ROP 2 7 0 
 
FIGURE 4 
 
 
64 
 
INCIDENCE OF ROP 
Among 100 babies studied in our hospital,  
Incidence of ROP was 38% (38/100 babies had any stage of ROP).  
Incidence of severe ROP was 9% (9/100) 
TABLE 5 
 TOTAL NO.BABIES (n=100) 
NO ROP 62 
MILD ROP 29 
SEVERE ROP 9 
 
FIGURE 5 
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In 9 cases of severe ROP, 
2 were treated with intravitreal bevacizumab and laser photocoagulation, 
7 were treated with only laser photocoagulation. 
 
FIGURE 6 
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RELATIVE WEIGHT GAIN CALCULATION: 
12 babies for whom extremes of relative weight gain observed were excluded in 
statistical analysis for obtaining precise results and all were in Group 1.  
Relative weight gain (g/kg/day) at second week of postnatal life was calculated as 
mean±SD 
Group 1: -2.55±3.55 
Group 2: -9.23±3.92 
FIGURE 7 
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Relative weight gain (g/kg/day) at fourth week of postnatal life was calculated as 
mean±SD 
Group 1: 3.12±3.71 
Group 2: -3.11±0.90 
 
FIGURE 8 
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Relative weight gain (g/kg/day) at sixth week of postnatal life was calculated as 
mean±SD 
Group 1: 7.35±4.14 
Group 2: -0.98±0.87 
 
FIGURE 9 
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COMPARSION OF RELATIVE WEIGHT GAIN BETWEEN TWO GROUPS: 
Relative weight gain between two groups were compared using unpaired student 
‘t’ test at second, fourth and sixth week of postnatal life and all found to be significant 
with P-value of <0.0001.  
TABLE 6 
RELATIVE WEIGHT 
GAIN (g/kg/day) 
NO ROP/MILD ROP SEVERE ROP P-VALUE 
SECOND WEEK -2.55±3.55 -9.23±3.92 <0.0001 
FOURTH WEEK 3.12±3.71 -3.11±0.90 <0.0001 
SIXTH WEEK 7.35±4.14 -0.98±0.87 <0.0001 
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For detection of severe ROP, Receiver Operating Curve (ROC) analysis showed,  
 
Cutoff of –6.2g/kg/day of relative weight gain calculated at second week of life 
(area under the curve 0.916; 95% confidence interval on the difference between the AUC 
and 0.5, 0.288-0.543) with 
 
Sensitivity of 88.9% and  
Specificity of 86.1%  
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For detection of severe ROP, ROC analysis showed,  
 
Cut off of –1.5g/kg/day of relative weight gain calculated at fourth week of life 
(area under the curve 0.946; 95% confidence interval on the difference between the AUC 
and 0.5, 0.342-0.550) with 
 
Sensitivity of 100% and  
Specificity of 89.9%  
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For detection of severe ROP, ROC analysis showed,  
 
Cut off of 1.1/kg/day of relative weight gain calculated at sixth week of life (area 
under the curve 0.974; 95% confidence interval on the difference between the AUC and 
0.5, 0.400-0.548) with 
 
Sensitivity of 100% and  
Specificity of 94.9% 
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SUMMARY OF RESULTS 
 Among 100 babies in this study, 62 had no ROP, 29 had mild ROP and 9 had 
severe ROP. Incidence of ROP was 38% and severe ROP was 9%.  
The mean GA in group 1 and group 2 were 32.24±1.43 weeks and 29.9±1.04 
weeks respectively.  
The mean BW in group 1 and group 2 were 1396.20±248.23 grams and 
1164.44±140.99 grams respectively. Statistical analysis showed babies with severe ROP 
had significantly lower BW and GA at birth.  
Out of 9 babies with severe ROP, 2 were treated with both intravitreal 
bevacizumab and laser photocoagulation and 7 were treated with only laser 
photocoagulation. 
Relative weight gain at second, fourth and sixth week of postnatal life were 
calculated and compared statistically between two groups and it was low in babies with 
severe ROP with significant P-value of <0.0001.  
For detection of severe ROP, ROC analysis identified cutoff value of -6.2g/kg/day 
of relative weight gain calculated at second week with sensitivity of 88.9% and 
specificity of 86.1%, -1.5g/kg/day of relative weight gain calculated at fourth week with 
sensitivity of 100% and specificity of 89.9% and 1.1g/kg/day of relative weight gain 
calculated at sixth week with sensitivity of 100% and specificity of 94.9%.  
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DISCUSSION 
ROP is caused by abnormal retinal vascular development in postnatal period. 
Identifying postnatal factors which have a predictive value in development and severity 
of ROP will be helpful for ROP screening and prevention.  
Clinical and animal studies showed that “low serum levels of IGF-1” and “poor 
postnatal weight gain” are associated with development of “severe form of ROP”.92,93 
Foundation for ROP screening is timely detection and treatment of severe ROP to 
get better visual outcome. 
Weekly measurements of weight in early postnatal period helps in detection of 
babies at risk for developing severe ROP weeks before may have significant positive 
effect on  care of these babies and predicting severe ROP in babies requiring deferment 
or rescheduling of ocular examination. 
Allagaert et al study showed poor absolute weight gain (g/day) but not relative 
weight gain in first 6 weeks of life was associated with threshold disease.
94 
Fortes Filho et al study showed low weight gain proportion at 6 weeks of life is an 
independent risk factor for development of ROP requiring treatment.
95 
These studies were different from our present study in that they used absolute 
weight gain or weight gain proportion in their studies. However, this have limitations in 
reflecting the true weight gain, because these premature babies were all born with 
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different BWs, and smaller babies are expected to have lower weight gain compared to 
larger babies. Therefore, the more appropriate definition is relative weight gain.  
This study calculated relative weight gain at second, fourth and sixth weeks of life 
and found that “poor relative weight gain at the second, fourth and sixth week of life was 
capable of predicting the development of severe ROP requiring treatment”. 
This is supported by study by Wallace et al and it showed that GA and poor 
relative weight gain in first 6 weeks of postnatal life were independent risk factors for 
development of ≥stage 3 ROP.96 
Aydemir et al also used a similar method and they found relative weight gain in 4
th
 
week of life was independently lower in babies with severe form of ROP.
97 
An online surveillance system was developed in Sweden based on BW 
measurements and serum IGF-1 levels weekly in the neonates. Weight IGF-1 Neonatal 
ROP (WINROP) algorithm was designed to detect the slow rise in IGF-1 levels or weight 
gain and was compared with values of infants those who have no ROP or only stage 1 
ROP. It has 100% sensitivity in detecting babies who will need treatment for ROP.  
Later it was modified that only serial weight measurements part of WINROP 
algorithm, excluding IGF-1 measurement was used, that can also predict severe ROP 
requiring treatment with 100% sensitivity. This algorithm was validated in Sweden and 
USA in a different cohort of infants.
98,99
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 In 2015 July, American Academy of Ophthalmology published evolving concepts 
in diagnosis and management of ROP, included poor postnatal weight gain as 
independent risk factor for developing ROP. 
IGF-1 is essential for the normal growth and development of many tissues 
including brain, retina and blood vessels. Preterm babies have lower serum IGF-1 level 
after birth due to poor endogenous production and loss of maternal source of IGF.
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Sepsis, intraventricular hemorrhage, bronchopulmonary dysplasia, and necrotizing 
enterocolitis, all act via common pathway that reduces IGF-1 level and are associated 
with development of ROP.  
 Serum IGF-1 concentration is strongly associated with postnatal weight gain and 
development of ROP in preterm babies. Postnatal weight gain is used as a surrogate 
measure for serum IGF-1 level.
101 
This explains the association of relative weight gain at the early postnatal period 
and development of severe ROP. 
This new approach helps to reduce the number of babies requiring stressful eye 
examination for ROP and precisely targeting babies at risk of developing severe ROP. 
This method helps to take more regulated follow up measures for babies with high 
risk to ensure visit compliance, decreasing the unfavourable outcome from missed ROP 
appointments, cost effective and readily available.  
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Early postnatal nutrition is important for postnatal weight gain. Human milk 
increases infants IGF-1 level and omega 3 fatty acid level that protect against ROP.  
New pharmacological treatments to improve physiologic retinal vascularisation 
e.g omega 3 polyunsaturated fatty acid supplementation, IGF-1 supplementation, 
erythropoietin supplementation have shown good results in animal studies, but more 
work is needed before considered for use in preterm infants.  
Many randomized clinical trials found the essential nutrient, inositol, to reduce the 
severity of ROP. Currently, a multicentre randomized clinical trial is underway. 
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CONCLUSION 
The results of this study showed that “poor postnatal weight gain” in early 
postnatal period is a predictor for development of “severe ROP” requiring treatment with 
laser photocoagulation and/ or anti-VEGF in our hospital. 
It helps in the prediction of the ROP much earlier in infants with poor postnatal 
course who are at the risk of developing severe ROP with possibility of new preventive 
treatment and avoids unnecessary stressful examination in preterm infants who are not at 
the risk of developing severe ROP. 
Thus, ophthalmologists and neonatologists should take special care and give more 
attention to the babies with poor postnatal weight gain to predict the disease much earlier 
before it is diagnosed by regular ocular examination that helps in early intervention and 
prevention of sight threatening complications.  
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PROFORMA 
Name of the Baby  :    Date of screening : 
Gender   :    Address  : 
Name of the Parent  :    OP / IP Number : 
Postnatal age   :    Birth place  : 
Single/multiple births :           Postnatal weight measurements 
DOB        First week  : 
Birth weight   :    Second week  : 
LMP:                       EDD :    Third week  : 
Gestational age at Birth :    Fourth week  : 
Postconceptional age    :    Sixth week   
Delivery mode                 :     
Gestational code             : 
Maternal factors  : 
Fetal risk factors       : 
Systemic examination  : 
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OCULAR EXAMINATION: 
 ANTERIOR SEGMENT  
OD  OS 
 Lids  
 Conjunctiva  
 Cornea  
 Anterior chamber  
 Iris  
 Pupil  
 Lens  
 White reflex  
 
 POSTERIOR SEGMENT 
OD  OS 
 Media  
 Disc  
 Retinal vessels  
 ROP-Zone, Stage  
 Clock hours involved  
 Fovea  
 Plus disease  
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Fundus diagram:       
 
 
 
Treatment advice: 
 
Follow-up advice: 
 
 
Follow up details: No.of visit/Date 
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MASTER CHART 
S.NO NAME SEX 
DELIVERY 
MODE 
SINGLE/ 
MULTIPLE 
BIRTHS 
GA AT 
BIRTH 
(WEEKS) 
BW 
(GRAMS) 
MATERNAL RISK 
FACTORS 
FETAL RISK 
FACTORS 
RELATIVE WEIGHT GAIN 
RETINAL 
FINDING 
(g/kg/day) 
1st 
week 
2nd 
week 
3rd 
week 
4th 
week 
6th 
week 
1 
B/O 
VIJAYALAKSHMI 
F NVD SINGLE 33 1300 
GEATATIONAL  
HYPERTENSION 
O2HOOD-13DAYS, 
SEPSIS, 
TRANSFUSION-
PLT4, FFP1, PC1 
-3.4 -1.4 0.8 2.5 4.9 NO ROP 
2 B/O DIVYA M LSCS SINGLE 33 1550 HYPOTHYROID SEPSIS -9.7 -4.6 -1.5 1.2 3.6 NO ROP 
3 B/O KALEESHWARI M NVD SINGLE 33 1250 PIH 
BIRTH ASPHYXIA, 
HIE, SEPSIS 
-6.1 -2.4 0.7 3.7 6.2 NO ROP 
4 B/O SATHYA M LSCS TWIN 29 1000 - 
BIRTH ASPHYXIA, 
DIAPHRAMATIC 
HERNIA, SEPSIS 
2.2 6.5 4.8 3.1 5.2 NO ROP 
5 B/O NAGAMMAL F NVD SINGLE 33 1750 - BIRTH ASPHYXIA -5.6 -2.4 0 9.2 15.5 NO ROP 
6 B/O SUNDARI RAJA M NVD SINGLE 34 1600 PIH, ANAEMIA 
MILD RDS, 
TRANSFUSION-
PLT3 
-3.4 0 1.6 3.6 7.2 NO ROP 
7 
B/O  
JOTHILAKSHMI 
F NVD SINGLE 33 1700 - O2 HOOD-1DAY -11.7 -5.4 1.2 2.2 8.7 NO ROP 
8 B/O BAKIYA M NVD SINGLE 32 1750 - 
RDS,  O2HOOD-4 
DAYS 
-12.5 -8.1 4.6 7.4 10.5 NO ROP 
9 
B/O PUTHU 
VASANTHAM 
F LSCS TWIN 34 1550 - 
RDS, O2HOOD-
2DAYS 
-13.6 -7.4 5.8 9.1 15.6 NO ROP 
10 B/O SUDHA M LSCS SINGLE 32 1150 - 
O2HOOD-3DAYS, 
TRANSFUSION-
PLT4,FFP5 
-10.6 -6.2 -4.6 -1.5 3.5 NO ROP 
11 B/O NALLAMAL F NVD SINGLE 33 1700 - 
BIRTH ASPHYXIA, 
CPAP-2 DAYS, 
O2HOOD-4DAYS 
-10.2 -4.3 0 10.3 15.5 NO ROP 
12 B/O ANBUSUDHA M LSCS SINGLE 34 1700 - 
RD, O2HOOD-
2DAYS, NEONATAL 
JAUNDICE 
-5.6 6.8 10.4 15 18.2 NO ROP 
13 B/O INDIRA F NVD SINGLE 32 1340 HYPOTHYROID,BOH 
RDS, CPAP-2DAYS,                 
O2-7 
DAYS,HIE,SEPSIS, 
TRANSFUSION – 
PLT3,WB1 
-6.2 -4.4 -3.7 -1.5 2.8 NO ROP 
14 B/O ROOPA M LSCS SINGLE 33 1750 - 
BIRTH ASPHYXIA,             
CPAP-3DAYS,               
O2HOOD-4DAYS 
-13.4 -7.7 3.4 10.4 22.6 NO ROP 
15 B/O MARISELVI M NVD SINGLE 31 1500 PIH O2HOOD-1DAY -18.4 -11.2 -6.3 -3.6 3.3 NO ROP 
16 B/O NAGALAKSHMI F NVD SINGLE 30 1000   
BIRTTH ASPHYXIA, 
RDS, SEPSIS 
-5.8 -1.4 1.2 3.6 8.2 NO ROP 
17 B/O VANATHI F LSCS SINGLE 34 1100 PIH O2HOOD-2DAYS -5.2 1.8 6.1 10.4 13.5 NO ROP 
18 B/O PANDISELVI M NVD SINGLE 32 1200 PIH 
BIRTH ASPHYXIA, 
CPAP-2DAYS, 
O2HOOD-2DAYS, 
SEPSIS, 
TRANSFUSION-
PLT2 
-6.2 0 1.4 3.4 7.3 NO ROP 
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S.NO NAME SEX 
DELIVERY 
MODE 
SINGLE/ 
MULTIPLE 
BIRTHS 
GA AT 
BIRTH 
(WEEKS) 
BW 
(GRAMS) 
MATERNAL 
RISK FACTORS 
FETAL RISK 
FACTORS 
RELATIVE WEIGHT GAIN 
RETINAL 
FINDING 
(g/kg/day) 
1st 
week 
2nd 
week 
3rd 
week 
4th 
week 
6th 
week 
19 B/O RAMALAKSHMI M LSCS SINGLE 31 1000 PIH, ANAEMIA 
RDS, CPAP-2DAYS, 
O2HOOD-2DAYS 
-6.2 -3.2 0 8.4 17.5 NO ROP 
20 B/O KALA F LSCS SINGLE 32 1500 ANAEMIA 
O2HOOD-3DAYS, 
SEPSIS 
-11.6 -6.6 -0.7 17.6 23.6 NO ROP 
21 B/O BOOPATHY F LSCS SINGLE 33 1500 ANAEMIA 
RDS, SURFACTANT, 
CPAP-12DAYS, 
O2HOOD-5DAYS 
-2.6 2.1 6.3 10.7 13.9 NO ROP 
22 B/O DIVYABARATHI M NVD SINGLE 32 1500 ANAEMIA RDS, O2HOOD-4DAYS -6.2 -2.3 0 2.3 8.3 NO ROP 
23 B/O AMIRTHAPRIYA M NVD TWIN 2 32 1500 - 
O2HOOD-1DAY, 
SEPSIS, CHOROID 
PLEXUS CYST 
-14.5 -7.2 -4.2 -2.4 3.4 NO ROP   
24 B/O AMIRTHAPRIYA M NVD TWIN 1 32 1200 - 
02HOOD-1DAY, 
STAPHYLOCOCCUS 
AUREUS SEPSIS 
-5.4 -1.8 1.3 4.5 13.8 NO ROP   
25 B/O KAVIARASI F NVD SINGLE 32 1500 PIH O2HOOD-1DAY, SEPSIS -7.4 -2.4 1.4 5.4 12.6 NO ROP   
26 B/O TAMIL SELVI F LSCS SINGLE 34 1375 PIH 
RDS, CPAP-4DAYS, O2 
HOOD-3DAYS, SEPSIS, 
TRANSFUSION-
FFP1,WB1 
-4.4 -1.8 3.6 8.4 14.6 NO ROP   
27 B/O KAVITHA F NVD SINGLE 30 1000 GDM 
RDS, O2HOOD-3DAYS, 
TRANSFUSION-PLT1 
-6.4 -3.6 1.7 4.1 17.8 NO ROP 
28 B/O KAVITHA F NVD SINGLE 31 1500 PIH 
RDS, CPAP-2DAYS, 
O2HOOD-5DAYS, 
TRANSFUSION-
FFP3,PLT1, IVH, ASD 
-8.2 -4.2 -2.3 5.4 7.1 NO ROP 
29 B/O THILAGAVATHY F NVD SINGLE 32 1000 PIH, ANAEMIA RDS, O2HOOD-2DAYS -9.4 -3.5 2.4 4.2 5.3 NO ROP   
30 B/OMEENAKSHI F LSCS SINGLE 28 1200 - O2-2DAYS -15.4 -9.2 -3.9 1.3 5.4 NO ROP   
31 B/O KARTHIGA M NVD TWIN 33 1400 HYPOTHYROID RDS, O2HOOD-4DAYS -6.2 -2.6 1.4 3.4 8.5 NO ROP   
32 B/O SOORYA F NVD TWIN 32 1350 - 
ROUTINE 
RESUSCITATION, 
SEPSIS 
-5.1 -1.9 1.6 3.4 5.8 NO ROP   
33 B/O PAUNTHAI M NVD SINGLE 33 1300 - 
RDS, O2HOOD-2DAYS, 
Rh-INCOMPATIBILITY, 
PFO 
-4.8 -1.6 2.2 4.1 7.5 NO ROP   
34 
B/O RAJESWARI 
PITCHAI 
M LSCS SINGLE 33 1650 PIH 
RDS, CPAP-5DAYS, 
O2HOOD-8DAYS, 
SEPSIS, 
TRANSFUSION-
FFP1,PLT4,  ASD 
-8.4 -2.8 0 2.3 5.6 NO ROP   
35 B/O PREMA M LSCS SINGLE 32 1750 - MILD RDS, SEPSIS -4.2 5.4 11.4 15.6 18.3 NO ROP   
36 B/O MANIKAVALLI M NVD SINGLE 31 1250 - 
O2HOOD-3DAYS, ASD, 
SEPSIS 
-4.2 -1.4 0 1.9 4.4 NO ROP   
37 B/O SUNDHARI M NVD SINGLE 34 1600 PIH O2 HOOD-1DAY -4.4 -1.8 2.2 6.4 12.6 NOROP 
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BW 
(GRAMS) 
MATERNAL 
RISK FACTORS 
FETAL RISK FACTORS 
RELATIVE WEIGHT GAIN 
RETINAL 
FINDING 
(g/kg/day) 
1st 
week 
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week 
3rd 
week 
4th 
week 
6th 
week 
38 B/O BEGAM F NVD SINGLE 32 1000 PIH 
RDS ,O2 HOOD-4DAYS, 
CPAP -2DAYS, SEPSIS 
-5.4 -1.2 1.1 3.8 13.4 NO ROP 
39 
B/O 
DHANALAKSHMI 
M NVD SINGLE 33 1250 PIH RDS, O2HOOD-3DAYS -7.4 -1.8 0 2.9 6.6 NO ROP 
40 B/O KARPAGAVALLI M NVD SINGLE 31 1500 PIH RDS, O2HOOD-4DAYS -4.8 -1.4 1.2 2.7 4.9 NO ROP 
41 B/O SARANYA F LSCS SINGLE 34 1200 PIH 
TRANSFUSION-
FFP4,PLT3, SEPSIS 
-9.7 -5.6 -2.5 1.8 4.6 NO ROP 
42 B/O SARITHA F LSCS SINGLE 33 1200 PIH O2HOOD-1DAY, ASD -6.2 -3.6 5.6 10.4 15.8 NO ROP 
43 B/O SELVI F LSCS SINGLE 34 1500 PIH 
ROUTINE 
RESUSCITATION 
-8.4 -1.2 5.4 9.4 14.8 NO ROP 
44 B/O SUBALAKSHMI F NVD SINGLE 33 1700 PIH, ANAEMIA O2HOOD-1DAY -5.2 1.7 4.2 6.1 10.2 NO ROP 
45 
B/O 
MUTHULAKSHMI  
F NVD SINGLE 32 1500 PIH 
RDS, O2-4DAYS, CPAP-
1DAY, TRANSFUSION-
2PLT 
-12.7 -5.6 -1.5 1.4 3.6 NO ROP   
46 B/O KANAGA M LSCS SINGLE 32 1600 PIH 
ROUTINE 
RESUSCITATION 
-5.6 2.7 7.6 10.4 16.2 NO ROP 
47 
B/O 
PALANIYAMMAL 
M LSCS SINGLE 33 1650 PIH SEPSIS -4.1 1.5 3.6 6.3 10.8 NO ROP 
48 B/O THANYA F NVD SINGLE 34 1500 PIH 
ROUTINE 
RESUSCITATION 
-11.7 -6.6 -1.5 1.4 5.6 NO ROP 
49 B/O THILAGA F LSCS SINGLE 34 1400 PIH O2HOOD-1DAY -4.3 0 2.4 4.8 8.2 NO ROP 
50 
B/O ALAGAMMAL 
PARAMASIVAM 
F NVD TWIN 32 1350 - RDS, O2HOOD-4DAYS -6.4 -1.1 -3.2 2.1 4.8 NO ROP 
51 B/O ALAGUPILLAI F NVD TWIN 32 1200 ANAEMIA 
RDS, SURFACTANT, 
CPAP-2DAYS, O2HOOD-
5DAYS 
-1.1 2.7 4.6 5.1 10.8 NO ROP 
52 
B/O MEENAKSHI 
MURUGAN 
M NVD SINGLE 31 1250 - 
RDS, SURFACTANT, 
O2HOOD-6DAYS, CPAP-
4DAYS, SEPSIS 
-11.5 -6.2 -2.6 2.4 6.3 NO ROP   
53 B/O ANNALAKSHMI F NVD SINGLE 33 1730 - 
ROUTINE 
RESUSCITATION 
-5.2 -1.1 2.6 3.2 8.8 NO ROP 
54 B/O SUBHA F NVD SINGLE 33 1750 - RDS,O2HOOD-2DAYS -9.7 -5.2 -1.5 1.2 5.1 NO ROP 
55 
B/O 
BHUVANESHWARI 
 F LSCS TWIN 34 1500 - SEPSIS -12.8 -6.4 0 3.8 10.6 NO ROP 
56 B/O DEIVAM F LSCS SINGLE 32 1500 - O2HOOD-3DAYS -12.2 -7.1 -2.7 0.8 3.8 NO ROP 
57 
B/O DHIVYA 
SENTHIL 
M NVD SINGLE 33 1400 - TRNSFUSION-PC2,FFP4 -9.1 -5.4 -1.4 2.2 7.4 NO ROP 
58 B/O KALPATHRANI M LSCS SINGLE 32 1650 - O2HOOD-3DAYS -7.4 -3.3 3.2 8.4 14.6 NO ROP 
59 B/O KANIMOZHI F NVD SINGLE 33 1720 ANAEMIA 
ROUTINE 
RESUSCITATION 
-4.2 1.4 4.2 7.4 13.1 NO ROP 
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60 
B/O PRIYA 
KUMARAVEL 
F LSCS SINGLE 32 1250 - 
RDS,O2HOOD-4DAYS, 
CPAP-1DAY, 
TRANSFUSION-
PLT4,FFP6 
-8.4 -3.6 -1.5 2.2 5.6 NO ROP 
61 B/O KOKILAVANI M LSCS SINGLE 33 1670 - O2HOOD-1DAY -6.2 -2.4 2.1 4.2 8.6 NO ROP 
62 B/O MUTHUMARI M NVD SINGLE 33 1300 HYPPOTHYROID 
MILD RDS, 
TRANSFUSION-
PL4,FFP3 
-7.1 -4.3 -1.6 5.6 11.3 NO ROP   
63 
B/O KALEESHWARI 
MUTHU 
M NVD SINGLE 29 1000 PIH 
BIRTH ASPHYXIA, 
CPAP-2 DAYS, 
O2HOOD-6 DAYS, HIE 
-4.5 2.14 4.5 6.6 9.5 MILD ROP 
64 
B/O SHANMUGA 
SUNDARI 
F NVD SINGLE 31 1500 ANAEMIA 
RDS, CPAP-6 DAYS, O2 
HOOD-2DAYS, SEPSIS 
-9.5 -3.3 -0.7 2.2 2.3 MILD ROP 
65 B/O SUDHA F LSCS SINGLE 33 1300 PIH 
RDS, CPAP -6 DAYS, 
O2 HOOD-3DAYS, 
SEPSIS 
-7.3 -3.5 3.2 5.4 6.2 MILD ROP 
66 B/O SANGEETHA F NVD SINGLE 28 1250 PIH 
BIRTH ASPHYXIA, 
CPAP-4 DAYS, O2 
HOOD-2 DAYS, SEPSIS 
-6.1 -3 -2.7 -2.1 0.6 MILD ROP 
67 B/O SHOBANADEVI F NVD SINGLE 32 1250 HYPOTHYROID 
RDS, CPAP-2 DAYS, 
O2-4 DAYS 
-2.3 -1.1 0 5.7 5.4 MILD ROP 
68 B/O RAJESWARI  F NVD SINGLE 34 1750 - 
CPAP-4 DAYS, SIMV-
5DAYS,  O2 HOOD-
5DAYS, SEPSIS 
-2.3 -1.3 0 1.3 6.1 MILD ROP 
69 
B/O 
MUTHALEESWARI 
M NVD SINGLE 31 1500 ANAEMIA 
ROUTINE 
RESUSCITATION 
-3.4 -1.9 -0.4 0.5 7.3 MILD ROP 
70 
B/O SUBITHA 
PRINCY 
F LSCS SINGLE 32 1600 GDM SEPSIS -5.7 -2.7 -1.3 0 4.5 MILD ROP 
71 B/O REKHA M NVD TWIN 31 1250 - 
MILD RDS, CPAP-
2DAYS, O2HOOD-
3DAYS 
-9.4 -5.7 -2.1 1.6 4.4 MILD ROP 
72 B/O NIVEDHA M LSCS SINGLE 34 1250 - 
RDS, O2HOOD-2DAYS, 
TRANSFUSION-PL3, 
FFP3 
-2.4 2.9 3.6 4.1 5 MILD ROP 
73 B/O LAKSHMI F NVD SINGLE 28 1100 ANAEMIA 
RDS, SURFACTANT 
GIVEN, CPAP-3DAYS, 
O2HOOD-5DAYS, 
APNOEA, 
TRANSFUSION-PL3 
-13 -8.4 -4.3 -3.3 1.1 MILD ROP 
74 
B/O 
MARIYAJAYANTHI 
F NVD SINGLE 32 1250 - 
RDS, SURFACTANT 
GIVEN, CPAP-1DAY, 
O2HOOD-2DAYS 
-6.2 -2.8 -1.9 1.4 4.3 MILD ROP 
75 B/O SAKTHIDEVI F NVD SINGLE 32 1300 ANAEMIA, PIH RDS, O2HOOD-3DAYS -11.7 -7.6 -6.1 -8.5 -2.1 MILD ROP 
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76 B/O CHANDRA F NVD SINGLE 33 1250 PIH, GDM 
RDS, CPAP-8DAYS, 
SIMV-6DAYS, 
SURFACTANT GIVEN, 
SEPSIS, PDA 
-11.2 -6.1 -5.9 -7 -1.9 MILD ROP 
77 B/O MUKILA M LSCS SINGLE 34 1500 PIH 
RDS,  SURFACTANT 
GIVEN, SIMV-4DAYS, 
CPAP-5DAYS, O2HOOD-
3DAYS 
-2.3 1.8 2.8 4.1 10.7 MILD ROP 
78 
B/O 
PANDEESHWARI 
F LSCS SINGLE 35 1250 
PIH, 
HYPOTHYROID 
BIRTH ASPHYXIA, 
CPAP-2DAYS, O2HOOD-
6DAYS, SEPSIS 
-2.1 2.9 7.5 8.9 15.8 MILD ROP 
79 B/O KAVIYA M NVD SINGLE 30 1500 - 
RDS, SURFACTANT 
GIVEN, CPAP-3DAYS, 
O2HOOD-3DAYS,HIE 
-9.8 -4.3 1.4 1.9 4.6 MILD ROP 
80 B/O ARUMUGADEVI M NVD SINGLE 32 1750 - 
RDS, SURFACTANT 
GIVEN, CPAP-8 DAYS, 
O2HOOD-8 DAYS,  
SEPSIS 
-6.3 -1.5 1.9 3.5 8 MILD ROP 
81 
B/O NATHIYA 
MALAISAMY 
F NVD SINGLE 30 1250 PIH, ANAEMIA RD, O2HOOD-3DAYS -6.4 -2.4 0.1 1.4 4.4 MILD ROP 
82 B/O USHA F NVD SINGLE 34 1700 - 
RDS, O2HOOD-3DAYS, 
SEPSIS, PDA 
-2.5 2.1 4.8 6.6 9.4 MILD ROP 
83 B/O VIMALA F LSCS SINGLE 33 1000 - O2HOOD-3DAYS -6.3 1.4 6.1 9.4 14.5 MILD ROP 
84 B/O RAJESWARI M LSCS SINGLE 33 1750 - O2HOOD-2DAYS, SEPSIS -6.3 -1.6 2.9 5.4 10.8 MILD ROP 
85 
B/O ANITHA 
PRABHAKARAN 
F NVD SINGLE 30 1000 - 
RDS, O2HOOD-
4DAYS,SEPSIS, HIE, 
TRANSFUSION-
FFP3,PLT3 
-11 -7.3 -5.8 -1.5 2.7 MILD ROP 
86 B/O MALAISELVI F LSCS SINGLE 34 1100 PIH O2 -1DAY, SEPSIS -8.33 -5.6 -7 -3 0.6 MILD ROP 
87 B/O RATHINAM F LSCS SINGLE 33 1500 HEART DISEASE  
BIRTH ASPHYXIA, 
CPAP-2DAYS, O2HOOD-
6DAYS, SEPSIS, HIE 
-3.1 0 5.4 7.6 9.1 MILD ROP 
88 B/O RAKKAMMAL F LSCS SINGLE 32 1000 PIH 
RDS,CPAP-3DAYS, 
O2HOOD-3DAYS, 
TRANSFUSION-
PLT5,FFP1 
-2.1 5.3 6.4 8.4 12.2 MILD ROP 
89 
B/O 
MURUGESHWARI 
THIRUMOORTHI 
F NVD SINGLE 29 1000 - 
BIRTH ASPHYXIA, 
CPAP-4DAYS, O2HOO-
6DAYS, SEPSIS, HIE, 
TRANSFUSION-
PLT3,FFP1 
-14.5 -8.4 -6.1 -2.1 2.5 MILD ROP 
90 B/O SUGANYA F NVD TWIN 32 1400 - 
RDS, CPAP-2DAYS, 
O2HOOD-7DAYS, HIE, 
SEPSIS 
-33 -18.3 -11.7 -6.4 -4.5 MILD ROP 
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S.NO NAME SEX 
DELIVERY 
MODE 
SINGLE/ 
MULTIPLE 
BIRTHS 
GA AT 
BIRTH 
(WEEKS) 
BW 
(GRAMS) 
MATERNAL 
RISK 
FACTORS 
FETAL RISK 
FACTORS 
RELATIVE WEIGHT GAIN 
RETINAL 
FINDING 
(g/kg/day) 
1st 
week 
2nd 
week 
3rd 
week 
4th 
week 
6th 
week 
91 B/O RAJESWARI M LSCS SINGLE 33 1570 PIH 
BIRTH ASPHYXIA, 
CPAP-2DAYS, 
O2HOOD-8DAYS, HIE 
-9.3 -5.3 3.2 9.6 18.4 MILD ROP 
92 B/O ASHTALAKSHMI F  NVD TWIN1 30 1300 - 
RDS, APNOEA, O2-
7DAYS, SEPSIS 
-23.6 -15.4 -9.6 -4.7 -1.8 SEVERE ROP 
93 B/O ASHTALAKSHMI M NVD TWIN2 30 1300 - 
RDS, APNOEA, O2-
5DAYS, SEPSIS 
-23.4 -13.1 -8.6 -3.8 -1.1 SEVERE ROP 
94 B/O PANDISELVI M NVD SINGLE 29 1150 - 
MILD RDS, O2-1DAY, 
SEPSIS, 
TRANSFUSION-PL2, 
PDA 
-20.5 -9 -6.6 -4 -1.4 SEVERE ROP 
95 B/O SHARMILA F NVD SINGLE 30 1250 - 
APNOEA OF 
PREMATURITY, 
SURFACTANT, CPAP-
4 DAYS, O2HOOD-
3DAYS, SEPSIS 
-17.6 -6.5 -6.8 -2.2 -1.6 SEVERE ROP 
96 B/O AZHAGUTHAI M NVD SINGLE 28 1050 PIH 
RDS, CPAP-18DAYS, 
O2HOOD-4DAYS, 
TRANSFUSION-PLT5, 
WB1 
-18.5 -6.4 -4.8 -3 -1.9 SEVERE ROP 
97 
B/O RAJESWARI 
MURUGAN 
F NVD SINGLE 28 930 - 
RDS, CPAP-1DAY, 
O2HOOD-10DAYS, 
SEPSIS, 
TRANSFUSION-PLT4 
-13.3 -4.4 -4.1 -3.1 -1.1 SEVERE ROP 
98 
B/O 
SIVAPANDIYAMMAL 
F NVD SINGLE 32 1200 - 
RDS, SURFACTANT 
GIVEN, APNOEA, 
CPAP-3DAYS, 
O2HOOD-5DAYS, 
TRANSFUSION-PL2, 
ASD 
-23 -14 -8.3 -2.9 -0.7 SEVERE ROP 
99 B/O  VAISHNAVI F NVD SINGLE 30 1000 - 
RDS, APNOEA, O2 
HOOD-4DAYS, CPAP-
2DAYS 
-15.8 -7.4 -4.9 -2.1 0.6 SEVERE ROP 
100 B/O SURYA M NVD SINGLE 32 1300 - 
RDS, SURFACTANT 
GIVEN, CPAP-5 DAYS, 
SIMV- 2DAYS, 
O2HOOD-5DAYS, 
SEPSIS, 
TRANSFUSION-
PLT10, PC2, FFP4 
-14.6 -6.9 -4.8 -2.2 0.2 SEVERE ROP 
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KEYS TO MASTER CHART 
GA      GESTATIONAL AGE 
BW         BIRTH WEIGHT 
PIH    PREGNANCY INDUCED HYPERTENSION 
RDS  RESPIRATORY DISTRESS SYNDROME 
O2  OXYGEN 
CPAP  CONTINOUS POSTIVE AIRWAY PRESSURE 
SIMV  SYNCHRONISED INTERMITTENT MECHANICAL VENTILATION 
LSCS  LOWER SEGMENT CAESERIAN SECTION 
NVD  NORMAL VAGINAL DELIVERY 
HIE  HYPOXIC ISCHAEMIC ENCEPHALOPATHY 
PLT  PLATELET 
WB  WHOLE BLOOD 
PC  PACKED CELL 
FFP  FRESH FROZEN PLASMA 
IVH  INTRAVENTRICULAR HEMMORHAGE 
ASD  ATRIAL SEPTAL DEFECT 
PFO  PATENT FORAMEN OVALE 
PDA  PATENT DUCTUS ARTERIOSUS 
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ABBREVIATION 
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ROP    RETINOPATHY OF PREMATURITY 
GA      GESTATIONAL AGE 
BW         BIRTH WEIGHT 
ET-ROP THE EARLY TREATMENT FOR RETINOPATHY OF PREMATURITY 
RLF  RETROLENTAL FIBROPLASIA 
CRYO-ROP   CRYOTHERAPY FOR RETINOPATHY OF PREMATURITY 
LIGHT-ROP   THE EFFECT OF LIGHT REDUCTION ON RETINOPATHY OF 
                         PREMATURITY  
VEGF              VASCULAR ENDOTHELIAL GROWTH FACTOR 
IGF-1    INSULIN LIKE GROWTH FACTOR 1 
CA     CHRONOLOGICAL AGE 
PMA    POST MENSTRUAL AGE 
NNF    NATIONAL NEONATOLOGY FORUM 
ICROP   THE INTERNATIONAL CLASSIFICATION FOR RETINOPATHY OF 
                         PREMATURITY 
AP-ROP   AGGRESSIVE POSTERIOR POLE RETINOPATHY OF  
    PREMATURITY 
PHPV             PERSISTANT HYPERPLASTIC PRIMARY VITREOUS 
BEAT-ROP  BEVACIZUMAB ELIMINATES THE ANGIOGENIC THREAT OF 
                       RETINOPATHY OF PREMATURITY 
RD  RETINAL DETACHMENT 
PUFA  POLY UNSATURATED FATTY ACID 
Epo  ERYTHROPOIETIN 
WINROP       WEIGHT IGF-1 NEONATAL RETINOPATHY OF PREMATURITY 
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